What Is PSSD? The Antidepressant Side Effect That Doesn't Always Go Away

For millions of people, SSRIs — selective serotonin reuptake inhibitors — are a critical tool for managing depression and anxiety. Most tolerate them well, and for many, any side effects that develop resolve once the medication is stopped. But for a subset of patients, that is not what happens.

Post-SSRI sexual dysfunction, known as PSSD, is a condition in which sexual side effects from antidepressants persist — sometimes for months, sometimes for years, sometimes indefinitely — after the medication has been discontinued. It has been formally recognized by European regulators, added to international medical coding systems, and is the subject of growing research. It is also, for many who experience it, one of the most isolating and least-understood diagnoses they will ever receive.

What Are the Symptoms?

PSSD is characterized primarily by sexual symptoms that do not resolve after stopping an SSRI or related medication. The most commonly reported include genital numbness, loss of libido, erectile dysfunction, reduced vaginal lubrication, and pleasureless or significantly weakened orgasm.

But the condition often extends beyond the sexual. Many patients report emotional numbing — a flattening of feeling that affects not just intimacy but everyday emotional life. Cognitive difficulties, fatigue, and a general sense of anhedonia — the inability to feel pleasure — are also frequently described. In some cases, symptoms that were mild while on the medication become worse after stopping it, which can make PSSD particularly confusing to identify.

The condition affects men and women across all ages and ethnic groups. It can develop after only a few days of antidepressant use, and there is currently no known cure.

Which Medications Are Linked to It?

PSSD is most commonly associated with SSRIs — among the most widely prescribed antidepressants in the world, including fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil). But the condition has also been reported with serotonin-norepinephrine reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine, and with some older tricyclic antidepressants including clomipramine and amitriptyline.

The common thread is their effect on serotonin — a neurotransmitter that plays a significant role in regulating both mood and sexual function.

How Does It Happen?

The exact mechanism behind PSSD is not yet fully understood, which is part of what makes it so difficult to treat. Researchers believe the prolonged exposure to serotonin-altering medications may trigger changes in receptor function or sensitivity that do not simply reverse when the drug leaves the body. Some studies have pointed to potential epigenetic effects — changes in how genes are expressed — as a possible explanation for why symptoms persist long after the medication is gone.

There is also some emerging evidence suggesting PSSD may involve damage to erectile tissue in men, though that research was presented at an academic conference in 2025 and has not yet been published in a peer-reviewed journal.

What is clear is that PSSD is not simply a continuation of the underlying depression or anxiety the medication was prescribed to treat. Diagnostic criteria published in 2022 specifically require ruling out other causes of sexual dysfunction before a PSSD diagnosis is made.

Is It Officially Recognized?

Yes — increasingly so, though recognition has been slow and uneven.

The European Medicines Agency has concluded that PSSD is a real medical condition and recommended that SSRI and SNRI product labels be updated to include information about the risk of persistent sexual dysfunction after stopping the medication. Health Canada issued a similar recommendation. In 2024, Australia's Therapeutic Goods Administration followed with a safety update requiring all SSRIs and SNRIs to carry warnings about this risk.

Also in 2024, PSSD was added to SNOMED CT — an international clinical terminology system used in electronic health records — meaning the condition can now be formally coded and recorded by healthcare providers. That may seem like a small administrative step, but for patients who spent years being told their symptoms were not real or not connected to their medication, it represents meaningful validation.

How Common Is It?

This is where the picture becomes less clear. There are no reliable estimates of how many people have PSSD. Tracking it is difficult because the condition is underreported, underdiagnosed, and only recently added to formal medical coding systems. Many patients never connect their symptoms to a medication they stopped taking months or years earlier. Others are told by their doctors that persistent sexual side effects are not a known phenomenon — advice that, in light of regulatory updates, is no longer accurate.

Research is ongoing. Patient advocacy groups have pushed for broader recognition for years, and scientific interest has grown substantially in the past decade. But a definitive prevalence figure does not yet exist.

Is There Any Treatment?

Currently, there is no proven treatment for PSSD. Various approaches have been explored — including dopaminergic medications like bupropion, PDE-5 inhibitors such as sildenafil, testosterone therapy, and cognitive behavioral therapy — but none have demonstrated consistent or reliable effectiveness in available research. Managing the condition is largely focused on symptom support and, where possible, addressing the psychological impact of living with a chronic and poorly understood condition.

What Should You Do If You Think You Have It?

Anyone who suspects they may have PSSD should speak with a doctor or mental health provider. The most important first step is ruling out other potential causes of sexual dysfunction, since that is part of the diagnostic process. It is also worth being aware that awareness of PSSD varies widely among clinicians — bringing documentation of regulatory guidance or published diagnostic criteria to an appointment can help facilitate a more informed conversation.

For those currently taking an SSRI or SNRI, the existence of PSSD is not a reason to stop medication without medical guidance. Untreated depression and anxiety carry their own significant risks, and the decision to adjust or discontinue any psychiatric medication should always be made in consultation with a prescriber.

If you are experiencing mental health challenges and want support, speaking with a doctor or licensed mental health professional is always a good first step.

Curious for more stories that keep you informed and entertained? From the latest headlines to everyday insights, YourLifeBuzz has more to explore. Dive into what’s next.